

Retinal toxicity of intravitreal drugs

Essay

Submitted for partial fulfillment
of master degree of ophthalmology

Presented by

Ehsan Mohamed Aly Hassan

M.B.,B.Ch.

University of Alexandria

Supervised by

Prof. Dr. Shaker Ahmed Khedr

Professor of ophthalmology

Faculty of Medicine

Ain Shams University

Dr. Mohamed Hanafy Hashem

Lecturer of ophthalmology

Faculty of Medicine

Ain Shams University

Faculty of medicine

Ain Shams University

Cairo-Egypt

2009

Table of contents

Subject	Page
Protocol	
List of abbreviation	III
List of figures	VI
List of tables	IX
Introduction	1
Aim of work	4
Pharmacodynamics.	5
Pharmacokinetics	8
Intravitreal injection:	14
Technique of Intravitreal Injection.	14
Strategies to Limit the Incidence of Defined Risk.	16
Sustained release intravitreal implants:	19
Advantages of sustained release drug delivery.	20
Disadvantages of sustained release drug delivery.	20
Technique.	20
Sustained release intravitreal Ganciclovir implant.	22
Sustained release intravitreal Cyclosporin implant.	24
Sustained release intravitreal Corticosteroid implants.	26
Anti vascular endothelial growth factors:	28
Age-related macular degeneration (AMD) and VEGF.	29
Role of anti VEGF in proliferative diabetic retinopathy.	42
Role of VEGF IN Retinopathy of prematurity.	45
Anti-inflammatory drugs:	
Triamcinolone	51
Dexamethasone.	61
Antiinfective drugs:	63
Antibacterial drugs.	63
Antiviral drugs.	67
Antifungal drugs.	83
Antiproliferative drugs:	
Fluorouracil.	90

Daunorubicin (Daunomycin).	92
Doxorubicin (Adriamycin).	93
Aclacinomycin A.	93
Antineoplastic drugs:	95
Methotrexate.	95
Bleomycin.	96
Fibrinolytic drugs:	97
T P A	97
Tenecteplase.	99
Antithrombin drugs:	100
Heparin.	100
L M W H	100
Hirudin.	101
Drugs acting on cell migration and contraction:	102
Colchicine.	102
Paclitaxel	103
Vitreous substitutes:	104
Silicon oil.	105
Perfluorocarbon liquid.	107
Miscellaneous:	109
Mitomycin-C.	109
Indocyanine Green.	110
Trypan blue.	111
Vitamin A.	111
Vitamin E.	112
Summary.	11
References.	118
Arabic summary	1

List of abbreviations

AIDS	Acquired immunodeficiency syndrome
AMB	Amphotericin B
AMBLC	Amphotericin B lipid complex
AMD	Age related macular degeneration
BAB	Blood-aqueous barrier
BRB	Blood retinal barrier
BRVO	Branch retinal vein occlusion
BSS	Balanced salt solution
CME	Cystoid macular edema
CMV	Cytomegalovirus
CMVR	Cytomegalovirus retinitis
CRVO	Central retinal vein occlusion
DHFR	Dihydrofolate reductase
DME	Diabetic macular edema
DNA	Deoxy ribonucleic acid
DR	Diabetic retinopathy Exudative age related macular
EAMD	degeneration
EC	Endothelial cell
EDTA	Ethylene diamine tetraacetic acid
ERG	Electroretinogram
ETDRS	Early Treatment Diabetic Retinopathy Study
ETROP	Early Treatment for Retinopathy of Prematurity
EVS	Endophthalmitis Vitrectomy Study
FA	Fluorescein Angiography
FDA	Food and Drug Administration
FEVR	Familial exudative vitreoretinopathy
F6H8	Perfluorohexyloctane
FLCZ	Fluconazole

5-FU	5-Fluorouracil
GCV	Ganciclovir
HIV	Human immunodeficiency virus
IC	Inhibitory concentration
ICG	Indocyanine green
ID50	Median infective dose
ILM	Internal limiting membrane
IOP	Intra ocular pressure
IVTA	Intravitreal Triamcinolone acetone
L-AMB	Liposomal amphotericin B
LMWH	Low-molecular-weight heparins
MGC	Multinucleated giant cells.
MIC	Minimum inhibitory concentration
MMC	Mitomycin C
MMC-TA	Mitomycin C Triamcinolone conjugate
NADPH	Nicotinamide adenine dinucleotide phosphate
NEI	National Eye Institute
NVD	Neovascularization at the disc
NVE	Neovascularization elsewhere
OCT	Optical coherence tomography
PCL	Polycaprolactone
PDR	Proliferative diabetic retinopathy
PDT	Photodynamic therapy
PED	Pigment epithelial detachment
PEDF	Pigment epithelium derived factor
PFC	Perfluorocarbon liquids
PFD	Perfluorodecalin
PKC	Protein kinase C
PLA	Poly lactic acid
PLGA	Poly (lactide-co-glycolide acid)
PRP	Panretinal photocoagulation

PVR	Proliferative vitreoretinopathy
RA	Retinoic acid
RPE	Retinal pigment epithelium
RNA	Ribonucleic acid
SAILOR	Safety Assessment of Intravitreal Lucentis for AMD
SiO	Silicone oil
Sub-RPE	Subretinal pigment epithelium
TAAC	Triamcinolone acetonide
Tfr-rRA	Transferrin-ricin A chain toxin
TPA	Tissue plasminogen activator
VA	Visual acuity
VEGF	Vascular endothelial growth factor
VISION	VEGF Inhibition Study in Ocular Neovascularization

List of figures

Figuer (1) Diagrammatic illustration of different methods Drug delivery to the posterior segment of the eye.	1
Figuer (2) (a) Cross-section of the human eye, (b)computational grid.	8
Figuer (3) Schematic presentation of the ocular structure with the routes of drug kinetics illustrated.	13
Figuer (4) Slit-lamp image of patient developed endophthalmitis after an intravitreal injection.	17
Figuer (5) Slit-lamp image of same patient Two weeks later, the eye is normal, due to fast intervention.	18
Figuer (6) Diagram of intravitreal implant.....	19
Figuer (7) Intravitreal implant surgical technique.	21
Figuer (8) Intraocular Ganciclovir implant.	23
Figuer (9) Diagramtic illustration of intraocular cyclosporine implant.	25
Figuer (10) Retisert implant.....	26
Figuer (11) Mechanism of action of anti VEGF.....	28
Figuer(12) Diagram illustrating VEGF expression, and changes with age leading to neovascular AMD.	30
Figuer (13) OCT results of bevacizumab intravitreal	

injection.	32
Figuer (14) Color fundus photographs with fluorescein angiographic images of bevacizumab intravitreal inject.	33
Figuer (15) Vial of Lucentis 0.5 mg single use vial.	33
Figuer (16) Diagram illustrating visual acuity over time for the MARINA, ANCHOR, and PIER Phase III trials.	35
Figuer (17) OCT ranibizumab for neovascular (AMD) demonstrating various patterns of recurrent (CNV) leakage... ..	37
Figuer (18) OCT, FA demonstrating RPE tear following intravitreal injection of bevacizumab.	40
Figuer (19) FA : Sccessful response to triple therapy with PDT,(IVTA) and ranibizumab intravitreal injection.	42
Figuer (20) FA :Retinal neovascularization, seen before, after and with discontinuation of pegaptanib injection.....	45
Figuer (21) Fundus photograph : Progression of ROP.	46
Figuer (22) Fundus photograph, OCT, late-phase FA: Diabetic macular edema.	51
Figuer (23) OCT: IVTA for refractory diabetic macular edema.	52

Figuer (24) Early phase FA and OCT showing classic subfoveal neovascularization.....	54
Figuer (25) Late phase FA and OCT showing cystoid macular edema.	55
Figuer (26) OCT: IVTA in retinal vein occlusion.	56
Figuer (27) F A of eye with amikacin toxicity.....	67
Figuer (28) F A of eye with amikacin toxicity.....	67
Figuer (29) Diagramatic illustration of effect of cidofovir on cytomegalovirus.	79
Figuer (30) Fundus photography of CMV retinitis(Cidofovir).	80
Figuer (31) Fundus photography of CMV retinitis (Foscarnet).	81
Figuer (32) Diagramatic illustration: Screening and management of CMV retinitis.	82
Figuer (33) Diagramatic illustration: Fungal Cell Structure.	83
Figuer (34) Mechanism of action of (amphotericin B).	84
Figuer (35) Mechanism of Action of Fluconazole.	86

List of Tables

Table (1) Maximum non toxic doses, toxic doses, and duration of therapeutic levels of anti-infective, antiviral and antifungal drugs after intravitreal injection.	89
Table (2) Material properties of the vitreous substitutes.....	103

Acknowledgments

Thank you my god for showing me the way giving me the strength and helping me to finish this work.

I'm deeply indebted to Prof Dr. Shaker Ahmed Khedr Prof of Ophthalmology Faculty of Medicine Ain Shams University for his kind encouragement and support, his valuable notes and advices and the great scientific help that helped me a lot in writing this essay, and lastly for his great patience.

I would like to express my deepest appreciation to Dr. Mohamed Hanafy Hashem Lecturer of Ophthalmology Faculty of Medicine Ain Shams University for his meticulous and extensive revision of this essay, for his kind cooperation and sincere support that help me to finish this work.

Ehsan Mohamed
Cairo-2009

Protocol

Retinal toxicity of intravitreal drugs

essay submitted for partial fulfillment
of master degree of ophthalmology

Presented by

Ehsan Mohamed Aly Hassan

M.B.,B.Ch.

Supervised by

Prof. Dr. Shaker Ahmed Khedr

Professor of ophthalmology



Faculty of Medicine-Ain Shams University



Dr. Mohamed Hanafy Hashem

Lecturer of ophthalmology

Faculty of Medicine-Ain Shams University



Faculty of medicine
Ain Shams University
Cairo-Egypt
2008

Introduction

A variety of systemic medications can generate retinal toxicity but fortunately, in the majority of cases the loss of visual function is minimal or reversible following discontinuation of the offending drug. However, in some cases, permanent or progressive visual loss may occur. Ocular toxicity may result from either over dose, chronicity of use, host susceptibility, or illegal abuse of medications. **(Blair JR, and Mierler WF, 1995.)**

The concentration of various drugs in the vitreous after systemic administration as a percentage of concurrent serum concentrations is poor unless the eye is inflamed. The vitreous humour drug concentration can reach as high as 10% of the serum drug concentration. **(Ogden TE, 1994.)**

Drug levels after systemic administration are the result of a dynamic process in which many factors play a role, these include, the serum concentration, drug protein binding, the lipid solubility of the drug, the active transport of the drug across the blood ocular barrier which is formed by two main barriers; the blood retinal barrier (BRB) and the blood aqueous barrier (BAB) and also the presence or absence of inflammation or any condition which may alter the blood ocular barrier. **(Lesar TS, and Fiscella RG, 1985.)**

Intraocular drug penetration may be enhanced by increasing the systemically administered dose. However,

increased systemic doses are often associated with significant side effects. **(Geroski DH, and Edelhauser HF,2001.)**

Because of the long delay in the drug delivery to the vitreoretinal compartement from systemic or subconjunctival injection, direct injection into the vitreal cavity (Intravitreal injections) is required, it provides the most direct approach for delivering drugs to the tissues of the posterior segment, and therapeutic tissue drug levels can be achieved. Intravitreal injections, however, have the inherent potential side effects of retinal detachment, haemorrhage, endophthalmitis, and cataract. Repeated injections are frequently required, and they are not always well tolerated by the patient. Since multiple intravitreal injections are traumatic to the patient, it is clear that means must be developed to sustain drug concentration in the vitreous cavity while minimizing its toxicity and enhancing its efficacy. These novel systems are called sustained release intravitreal implants. **(Velez G and Whitcup SM, 1999.)**

The possible danger of intravitreal injection has limited its use to conditions at which the eye is at high risk for considerable visual loss. These may include endophthalmitis, proliferative vitreoretinopathy, tumors, and severe inflammation. The danger of injection may be somewhat overstated; it is probably safe when administered carefully. **(Peyman GA, et al., 1992.)**